Last update Jan. 11, 2023

A05AA01

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

It is a natural bile acid present in human bile. It suppresses the hepatic synthesis and secretion of cholesterol and inhibits the intestinal absorption of cholesterol. It is an epimer of ursodeoxycholic acid. It is used for the treatment of primary biliary cirrhosis and the dissolution of gallstones. Oral administration one to three times a day.

At the date of the last update we did not find any published data on its excretion in breast milk, but since it is an epimer of ursodeoxycholic acid, compatible with breastfeeding, similar pharmacokinetics are to be expected.

It is a bile salt that partially epimerizes to ursodeoxycholic acid that appears in very low levels in the serum (and breast milk) because it is delivered to portal circulation and completely excreted by the liver through the bile duct.

It has been used as a dietary supplement in neonates and children with inborn errors of bile acid synthesis.

Bile salts are found in breast milk in small amounts (Forsyth 1983). Altered bile acid ratios in breast milk have been linked to prolonged jaundice from breastfeeding. (Forsyth 1990)


See below the information of this related product:

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

A05AA01 is Chenodeoxycholic Acid (CDCA) in ATC Code/s.

Is written in other languages:

A05AA01 is also known as

Group

A05AA01 belongs to this group or family:

Tradenames

Main tradenames from several countries containing A05AA01 in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 393 daltons
pKa 4.6 -

References

  1. Crosignani A, Setchell KD, Invernizzi P, Larghi A, Rodrigues CM, Podda M. Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet. 1996 May;30(5):333-58. Review. Abstract
  2. Forsyth JS, Donnet L, Ross PE. A study of the relationship between bile salts, bile salt-stimulated lipase, and free fatty acids in breast milk: normal infants and those with breast milk jaundice. J Pediatr Gastroenterol Nutr. 1990 Aug;11(2):205-10. Abstract
  3. Forsyth JS, Ross PE, Bouchier IA. Bile salts in breast milk. Eur J Pediatr. 1983 Apr;140(2):126-7. Abstract

Total visits

706

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM